Beth Rogozinski is a serial entrepreneur, technology professional, and business strategist who has spent the last several years focused on digital medicine. Beth has worked in hardware, software and services at such top firms as Silicon Graphics, Macromedia, and the digital agency Circle and has also founded games and apps companies including Signal 2 Productions, Match Factor and D2S Games. She has produced and published more than 30 games and apps, including over a dozen apps for health and wellness. As Chief Product Officer at Pear Therapeutics, Beth led the development of Pear’s first clinical products and the product team submission of the De Novo 510k to the FDA. Pear’s ReSET™ was cleared by the FDA in 2017 as the first ever prescription digital therapeutic. Beth is board director or advisor to many start-ups and accelerators and has consulted with health and innovation centers such as Stanford University, UnitedHealth Group and the National Mental Health Innovation Center, as well as local and international venture groups. Beth is a guest lecturer and mentor in the UCSF Health Hub, at Columbia’s HIT Lab and serves on BIO’s committee for Digital Health. She has written and published on digital medicine and tech innovations and is a frequent speaker at technology and healthcare events.
Beth is currently CEO of Oncoustics, an innovative AI solutions company that is creating low cost, non-invasive surveillance, diagnostics, and treatment monitoring for diseases with high unmet clinical need.